Kirsti Gjellan - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 29.50  0.00  0.00%

Ms. Kirsti Gjellan serves as Senior Vice President, Head of Biologics Development Supply at Swedish Orphan Biovitrum AB . She joined the Company in 2014. She is Pharmacist and holds a Doctorate of Philosophy degree in Pharmaceutical Technology from Universitetet i Oslo. Previously she was Factory Director, Biologics Manufacturing, MD at Pfizer Health AB and Board Member of Pfizer Health AB . She was also Director of Quality Operations, Pfizer . She has 17 years of experience from senior positions in research and manufacturing medicines at Astra Zeneca. She is also Board member of Processindustriell IT and Automation .
Age: 53        
46 86 97 20 00

Management Efficiency

The company has return on total asset (ROA) of 13.63 % which means that it generated profit of $13.63 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 27.22 % meaning that it generated $27.22 on every $100 dollars invested by stockholders.
The company has accumulated 788.2 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.96 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Stuart TrossAmgen
Taiyin YangGilead Sciences
Marion McCourtRegeneron Pharmaceuticals
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Michael PariniVertex Pharmaceuticals Incorpor
Jay MarkowitzRegeneron Pharmaceuticals
Bob RepellaCSL Limited
Susan AlexanderBiogen
Joseph LaRosaRegeneron Pharmaceuticals
William LeeGilead Sciences
Steven HoltzmanBiogen
Andrew DickinsonGilead Sciences
Jacqualyn FouseCelgene Corporation
Jeffrey CapelloBiogen
Laurie ReedCSL Limited
Anirvan GhoshBiogen
Paul CarterGilead Sciences
Thomas DanielCelgene Corporation
Michel VounatsosBiogen
Henry FuchsBioMarin Pharmaceutical
Howard MayerShire plc

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 842 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Independent Director
Lennart Johansson, Director
Annette Clancy, Independent Director
Trista Morrison, Vice President - Communications for North America
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Rami Levin, Head of North America
Norbert Oppitz, Head of Specialty Care
Hans Schikan, Independent Director
Dennis Pedersen, Senior Vice President Human Resources
Helena Saxon, Director
Anders Edvell, Head of Marketing and Sales
Philip Wood, Head of Haemophilia
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
Fredrik Wetterlundh, Head of Human Resources
BoGunnar Rosenbrand, Director, Employee Representative
Adine Axen, Independent Director
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Hege Hellstrom, Head of EMENAR
Catarina Larsson, Director, Employee Representative
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Torbjorn Hallberg, General Counsel and Head of Legal Affairs
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Pia Axelsson, Director, Employee Representative
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Theresa Heggie, Independent Director

Stock Performance Indicators

Did you try this?

Run Equity Search Now


Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Equity Search

Swedish Orphan Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Swedish Orphan and Amgen. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.